Dongyangguang Pharma (06887.HK): Ologliptin Capsules Successfully Included in the 2026 National Medical Insurance Drug Catalog

Zhitong Finance APP News, HEC Pharm (06887.HK) announced that recently, the Group's independently developed sodium-glucose transport protein 2 inhibitor (SGLT-2 inhibitor), a Class 1 innovative drug, Olagliptin Capsules (trade name: Dongze'an), has been successfully included in the latest edition of the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" published by China's National Healthcare Security Administration. The 2026 edition of the National Medical Insurance Drug Catalog will be officially implemented starting January 1, 2027.